cyrilzakka/clinical-trials huggingface dataset:
Randomized Trial of Two Analgesics in Elderly ED Patients

The purpose of this study is to perform a randomized, double blind 2-arm clinical trial of the comparative efficacy of 2 oral analgesics in the the management of acute pain in elderly patients who present and then are discharged from the ED.

To perform a randomized, double blind 2-arm clinical trial of the comparative efficacy of 2 oral analgesics in the the management of acute pain in elderly patients who present and then are discharged from the ED.. The 2 groups are as follows:

1. Oxycodone/acetaminophen (5/325)
2. Ibuprofen/acetaminophen (400/500)

Eligibility Criteria:
Inclusion Criteria:

* Complaint of acute pain of \< 7 days duration
* ED attending plans to discharge patient home with an oral analgesic

Exclusion Criteria:

* Inability to confirm reliable means of phone followup.
* Past use of methadone
* Chronic condition requiring frequent pain management such as sickle cell disease, fibromyalgia, or any neuropathy
* History of an adverse reaction to any of the study medications
* Ibuprofen or acetaminophen or opioids taken in past 4 hours
* History of peptic ulcer disease
* Report of any prior use of recreational narcotics
* Medical condition that might affect metabolism of opioid analgesics, acetaminophen, or ibuprofen such as hepatitis, renal insufficiency, hypo- or hyperthyroidism, Addison's or Cushing's disease
Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients

The quality of colon cleansing has a major impact on efficiency and cost of colonoscopy. A hand-out was made to instruct and motivate patients to adequately clean the bowel before colonoscopy.

The aim of the study is to compare adequacy of bowel cleansing in hospitalized patients receiving the hand-out or not on the day before colonoscopy.


Eligibility Criteria:
Inclusion Criteria:

* Total colonoscopy scheduled during hospital stay in the Hôpital Universitaire de Genève (excluding dependencies);
* Informed consent for inclusion in the study signed by the patient;
* Ability to read and write at least one of the following languages : French, English, Spanish, Portuguese.

Exclusion Criteria:

* Colonoscopy scheduled under general anesthesia;
* Occupation inside the healthcare professions;
* Previous colonoscopy, colostomy or colectomy;
* Megacolon or idiopathic pseudo-obstruction.
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.

JNJ-70033093 is an oral anticoagulant for prevention and treatment of thromboembolic events (for example, VTE) that binds and inhibits activated form of human coagulation Factor XI (FXIa) with high affinity and selectivity. The study will consist of 3 phases: up to 30-day screening phase before total knee replacement (TKR) surgery, 10 to14 day postoperative dosing phase, and 4-week follow-up phase. The hypothesis of this study is JNJ-70033093 reduces risk of total VTE during treatment period. The total duration of participation following randomization will be approximately 6 weeks. Efficacy evaluations include unilateral venography assessment of operated leg and assessments of symptomatic DVT, PE, or death. Safety evaluation includes adverse events, clinical laboratory tests, and physical examinations. The safety and efficacy will be monitored throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Medically stable and appropriate for anticoagulant prophylaxis as determined by the investigator on the basis of physical examination, medical history, and vital signs performed as part of screening for elective total knee replacement (TKR) surgery
* Medically stable and appropriate for anticoagulant prophylaxis on the basis of clinical laboratory tests performed as part of local standard-of-care as part of screening for elective TKR surgery
* Has plans to undergo an elective primary unilateral TKR surgery
* A woman must be- a) Not of childbearing potential; b) Of childbearing potential and practicing a highly effective method of contraception (failure rate of less than \[\<\]1 percent \[%\] per year when used consistently and correctly) and agrees to remain on a highly effective method for the duration of study drug with JNJ-70033093 plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle) for a total of 34 days after the completion of treatment, pregnancy testing (serum or urine) prior to the first dose of study drug
* Willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria:

* History of any condition for which the use of low molecular-weight heparin (LMWH) is not recommended in the opinion of the investigator (for example, previous allergic reaction, creatinine clearance \<30 milliliter per minute \[mL/minute\])
* History of severe hepatic impairment
* Planned bilateral revision or unicompartmental procedure
* Unable to undergo venography (for example, due to contrast agent allergy, poor venous access, or impaired renal function that would increase the risk of contrast-induced nephropathy
* Known previous pulmonary embolism (PE) or deep vein thrombosis (DVT) in either lower extremity
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients

There is still no perfect treatment suggestion for patients with asymptomatic colorectal cancer with unresectable metastatic disease. Whether patients can benefit from palliative resection of primary tumor or not is still waiting for answer. The investigators hypothesis that asymptomatic metastatic colorectal cancer patients who respond to chemotherapy will benefit from primary tumor resection.


Eligibility Criteria:
Inclusion Criteria:

* 18 to 70 years old
* both genders
* ECOG:0-2 score
* Pathological confirmed colon cancer or rectal cancer with at least 12 cm far away from anal verge
* CT,MRI,or PET-CT confirmed metastasis
* MDT confirmed unresectable metastasis lesion
* No evidence of obstruction, bleeding, perforation
* WBC≥4.0×109/L，Neu ≥2.0×109/L，PLT≥100×109/L
* No contraindication for chemotherapy
* No evidence of other malignant tumor
* Expected survival time \> 6 months

Exclusion Criteria:

* mCRC patients who did not respond to first line chemotherapy
* Require surgical intervention during the primary tumor-related symptoms
* Obvious coagulopathy
* Severe heart, liver, kidney damage or other serious uncontrolled medical illness or acute infection, cachexia
* Severe organ damage after chemotherapy, surgery or unable to continue to systemic chemotherapy
* Pregnant or lactating women or women of childbearing age who refuse to accept contraception.
* Nearly three months participated in clinical trials of other persons.
* Mental abnormalities
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes

Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied. The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.

Sphingolipids represent a major class of lipids that are structural and signaling molecules. Major bioactive sphingolipids include ceramide, dihydroceramide, sphingosine, sphingosine-1-phosphate and sphingomyelin.

Sphingoliplids are involved in development of various chronic metabolic diseases. Some ceramides species are implicated in pancreatic β-cell apoptosis and in insulin resistance in muscle, fat and liver. Some studies have shown association between inhibition of ceramide synthesis, insulin sensibility and lower hepatic steatosis. The deposition of hepatic lipids, especially triacylglycerol, defines the development of hepatic steatosis. However, sphingolipids appear to play an important role in non-alcoholic fatty liver disease (NAFLD) and in its progression. Changes in plasma shingolipids concentrations may also contribute to the pathogenesis in cardiovascular disease and atherosclerosis. Distribution of plasma sphingolipids concentrations in type 1 and type 2 diabetes has poorly been studied.

The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.

Eligibility Criteria:
Inclusion Criteria:

* type 1 or 2 diabetes

Exclusion Criteria:

* atypical diabetes

  * family dyslipidemia
  * nonmetabolic hepatopathy
  * severe renal failure
  * corticosteroid or immunosuppressive therapy
Pontos-Central Venous Pressure and Cardiac Surgery

Recent studies indicated the central venous pressure (CVP) as a prognostic marker. Therefore, we retrospectively analyzed the CVP on admission to the intensive care unit (ICU) in cardiac surgery patients regarding its prognostic value for morbidity and mortality.


Eligibility Criteria:
Inclusion Criteria:

* In-patients of the Charité Universitätsmedizin Berlin
* at least 18 years old
* female or male sex
* cardiosurgical intervention (OPS 5.35 and 5.36) between 01/06 and 12/13.
* post-operative monitoring of anesthesiological intensive care unit

Exclusion Criteria:

* previous cardiosurgical interventions during the same hospital stay.
* incomplete documentation
The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis

This study will consist of a brief interaction with the subject or parent or guardian to obtain consent, collect a blood sample, medical history, and physical examination of those who meet the inclusion criteria. The blood sample will be tested for the WBC value, as well as processed into plasma in order to compute the APPY1 Test result, which is based on a combination of the WBC value and the plasma MRP 8/14 and CRP concentrations received from the APPY1 Test cassette. There will be a 2-week (14 days +/- 3) follow-up telephone call for those subjects that were discharged from the ED without an appendectomy or diagnosis of acute appendicitis. Use of the APPY1 Test to help identify low risk patients could significantly reduce the use of CT scans in diagnosis of AA, thereby reducing the exposure to ionizing radiation in children, adolescents, and young adults.


Eligibility Criteria:
Inclusion Criteria:

* 2 to 20 years old (up until the 21st birthday),
* Right lower quadrant or poorly localized abdominal pain, or tenderness that includes the right lower quadrant, and/or other features including, but not limited to, nausea, vomiting, and/or anorexia, requiring acute appendicitis to be added to the differential,
* Onset of abdominal pain within 72 hours or less,
* Patients of either gender may participate and,
* Patient or accompanying parent or guardian is able to provide informed consent.

Exclusion Criteria:

* History includes prior appendectomy,
* Subjects whose presentation history and physical examination place them at such high risk of acute appendicitis that it would be clinically reasonable to proceed with exploratory laparotomy and/or appendectomy without advanced imaging,
* Treatment with any immunosuppressive medication or chemotherapeutic agents within 28 days, or systemic steroids (oral or intravenous) within 14 days,
* History of end-stage, metastatic cancer or an active immune disorder,
* History includes abdominal trauma or invasive abdominal procedures/surgery within the previous two weeks,
* Patients who have received diagnostic imaging (CT, MRI, or US) for abdominal pain in the previous two weeks,
* Patients with report of abdominal pain greater than 72 hours,
* History of active bleeding disorder, which may complicate phlebotomy or placement of peripheral IV catheter,
* Participation in a research study within the previous 30 days,
* Prisoners of an adult or juvenile detention center, and
* Subject, parent or guardian unable to provide informed consent.
Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion

This study will investigate the absorption, distribution, metabolism and excretion after giving 2000 mg 14C-SLV334 via a 1-hour infusion. The absolute bioavailability will also be determined.


Eligibility Criteria:
Inclusion Criteria healthy non-smoking subjects Exclusion Criteria QTc \> 430 ms; positive drug screen
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.


Eligibility Criteria:
Inclusion Criteria:

1. Histologically confirmed NASH diagnosis as defined by the NASH CRN
2. Total liver fat content of ≥ 8% as measured by MRI-PDFF

Exclusion Criteria:

1. Clinically significant acute or chronic liver disease of an etiology other than NASH
2. Evidence of drug-induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis
3. History or presence of cirrhosis (compensated or decompensated) as determined by histology and/or relevant medical complications and/or laboratory parameters
4. Prior or pending liver transplantation

Other protocol-defined inclusion/exclusion criteria could apply.
Renal Replacement Therapy in Neonates

The circumstances for setting up dialysis in the neonatal period are multiple: congenital anomaly of the kidney and urinary tract (CAKUT), secondary acute renal failure whose etiologies are multiple (sepsis, hypovolemia, respiratory distress syndrome, neonatal asphyxia, Arterial or venous renal thrombosis, nephrotoxic drugs, etc.), metabolic diseases (mainly hyperammonemia and leucinosis) and post-operative management of heart disease: analysis of the characteristics of the patients in our study and comparison with existing epidemiological data in the literature.

The decision to set up dialysis in a newborn whose recovery of renal function is uncertain or in a context of acute multi-visceral failure is not always obvious and must be discussed carefully. multidisciplinary in connection with neonatologists, resuscitators and nephrologists as well as families with the consideration of the future quality of life of the child.


Eligibility Criteria:
Inclusion criteria:

* Minor under 28 days old
* Having benefited from a renal purification technique in the pediatric intensive care unit of the University Hospital of Strasbourg
* Holders of parental authority who do not object to the reuse of their child's data for scientific research purposes.

Exclusion criteria:

- Holders of parental authority who have expressed their opposition to the reuse of their child's data for scientific research purposes.
Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension

The purpose of this study is to assess the efficacy and safety of Chlorthalidone 25 mg + amiloride hydrochloride 5 mg association in the treatment of elderly patients with arterial hypertension.

To assess the efficacy and safety of the association of Chlorthalidone 25 mg + amiloride hydrochloride 5 mg (Diupress® Eurofarma) in the treatment of elderly patients with arterial hypertension, compared to Chlorthalidone 25mg (Higroton® Laboratório Novartis) in same presentation form.

Some eligibility criteria:

perform blood and urine tests; ECG (electrocardiogram); ABPM (Ambulatory Blood Pressure Monitoring; Echocardiogram;Doppler Echocardiogram

Eligibility Criteria:
Inclusion Criteria:

* Systolic blood pressure between 140 mmHg - 159 mmHg
* Diastolic blood pressure between 90 mmHg - 99 mmHg
* Subject aged ≥ 60 years old
* Be able to comply with instructions, attend study follow-up visits and be willing to participate in the research project.
* Diagnosis of stage 1 arterial hypertension with no prior treatment more than 120 days or uncontrolled during antihypertensive agent administration.

Exclusion Criteria:

* Any serious or severe clinically significant medical condition.
* Psychiatric or neurological diseases
* A condition that, as per Principal Investigator's opinion, may interfere with the optimal participation in the study, or that may result in special risk to the patient.
* Participation in any other investigational study within 12 months prior to Visit 1.
* Known medical history of allergy, hypersensitivity or intolerance to any of the formulation compounds to be used in this study
* Routine prior use of diuretics
* Oral anticoagulant use
* Fast glycemia \> 150 mg/dL
* Medical treatment, not related to study, scheduled for the clinical trial duration; except non-serious, controlled comorbidities in current medical follow-up.
* Expected onset of additional antihypertensive drug after the study onset
* Acute myocardial infarction within last 6 months
* Prior decompensated coronary artery disease
* Known thyroid, renal or liver dysfunction, at investigator's discretion
* Obesity - body mass index (BMI) \> 33 kg/m2
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations

The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios.

The main question aims to answer are:

* How do large language models perform in comparison to human doctors in diagnosing and consulting on respiratory diseases across various clinical scenarios?

In three clinical scenarios including the online query section, the disease diagnosis section and the medical explanation section, research assistants or volunteers will be asked to cross-question all LLMs or real doctors using predefined online questions and their own issues. After each questioning session, a short washout period is implemented to eliminate potential biases.


Eligibility Criteria:
Inclusion Criteria:

1. Self-reported symptoms of common respiratory diseases, such as cough, chest tightness, fever, and wheezing
2. Ability to engage in LLM dialog operations independently or with minimal peer training
3. A health status deemed suitable for study participation by the pulmonology experts

Exclusion Criteria:

1) Excessively poor health status
Effect of Probiotic Lacobacillus Reuterii on Serum Bilirubin Levels in Preterm Infants

The goal of this clinical trial is to learn about the effect of probiotic Lactobacillus reuterii on the level of serum bilirubin in moderately and late preterm infants with birth weights 1000 grams to 2499 grams who were admitted to the NICU at Dr. Wahidin Sudirohusodo Hospital, Hasanuddin University Hospital and Cahaya Medika Hospital. The main questions it aims to answer are:

* Are bilirubin levels in preterm infants who received probiotics were lower than those who did not receive probiotics?
* Is the incidence of hyperbilirubinemia requiring phototherapy in preterm infants who received probiotics less than those who did not receive probiotics?

This study aims to investigate the effect of probiotic Lactobacillus reuteri administration on serum bilirubin levels in preterm infants. It is a randomized controlled trial conducted at the Neonatal Intensive Care Units of Dr. Wahidin Sudirohusodo Hospital, Hasanuddin University Hospital and Cahaya Medika Hospital in Makassar, South Sulawesi, Indonesia. The study population includes infants born at 32 to \<37 weeks gestational age with birth weights between 1000-2499 grams who are admitted to the NICU. Eligible infants are randomized into two groups - an intervention group receiving probiotic L. reuteri (5 drops daily for 7 days) and a control group not receiving probiotics. The primary outcome is serum bilirubin levels, measured at baseline and after 7 days of intervention. Secondary outcomes include incidence of hyperbilirubinemia requiring phototherapy and changes in bilirubin levels in those receiving phototherapy. Blood samples are collected to measure total and direct bilirubin levels. The study aims to enroll 40 infants (20 per group) to detect a clinically meaningful difference in bilirubin levels between groups. This trial will provide evidence on whether probiotic supplementation with L. reuteri can reduce the severity of hyperbilirubinemia in preterm infants. The results may inform clinical practice regarding the use of probiotics as an adjunctive therapy for neonatal jaundice in this vulnerable population.

Eligibility Criteria:
Inclusion Criteria:

* Premature Infants (32 - \< 37 weeks gestation)
* Birth weight 1000 - 2499 grams
* Sick infants who are treated in the NICU
* Preterm infants who received enteral feeding \> 30 cc/kgBB less than 72 hours after birth, without jaundice or jaundice Kremer 1,2, and 3
* Parents have signed their child's consent to participate in the study

Exclusion Criteria:

* Infants with multiple congenital abnormalities
* Infants with jaundice before 24 hours or having jaundice cremer \> 4 less than 72 hours from birth
* Infants with Sepsis, Metabolic acidosis